• 1
    Blake DR, Meigs JB, Muller DC et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004; 53: 2095-2100.
  • 2
    Festa A, D'Agostino R, Howard G, Mykknen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
  • 3
    Orchard T J, Temprosa M, Goldberg R et al.; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619.
  • 4
    Haffner S. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92: 18J-26J.
  • 5
    Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723.
  • 6
    Houmard JA, Tanner CJ, Slentz CA et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol 2004; 96: 101-106.
  • 7
    Dela F, Larsen JJ, Mikines KJ et al. Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes 1995; 44: 1010-1020.
  • 8
    Holten MK, Zacho M, Gaster M et al. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 2004; 53: 294-305.
  • 9
    Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 2002; 22: 385-398.
  • 10
    Herder C, Peltonen M, Koenig W et al.; Finnish Diabetes Prevention Study Group. Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia 2009; 52: 433-442.
  • 11
    Bacon SL, Sherwood A, Hinderliter A, Blumenthal JA. Effects of exercise, diet and weight loss on high blood pressure. Sports Med 2004; 34: 307-316.
  • 12
    Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-2081.
  • 13
    Lehtovirta M, Forsén B, Gullström M et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med 2001; 18: 578-583.
  • 14
    Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067.
  • 15
    DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
  • 16
    Rhee MK, Herrick K, Ziemer DC et al. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 2010; 33: 49-54.
  • 17
    Driscoll SD, Meininger GE, Lareau MT et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18: 465-473.
  • 18
    Andreadis EA, Katsanou PM, Georgiopoulos DX et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects-the Carmos study. Exp Clin Endocrinol Diabetes 2009; 117: 175-180.
  • 19
    Malin SK, Gerber R, Chipkin SR, Braun B. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 2012; 35: 131-136.
  • 20
    Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-486.
  • 21
    Johnson JL, Slentz CA, Houmard JA et al. Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am J Cardiol 2007; 100: 1759-1766.
  • 22
    Fleiss JL. Statistical Methods for Rates and Proportions. John Wiley: New York, 1981, pp 114.
  • 23
    Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008; 22: 215-224.
  • 24
    Church TS, Martin CK, Thompson AM et al. Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women. PLoS ONE 2009; 4: e4515.
  • 25
    Donnelly JE, Hill JO, Jacobsen DJ et al. Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial. Arch Intern Med 2003; 163: 1343-1350.
  • 26
    Clarson CL, Mahmud FH, Baker JE et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine 2009; 36: 141-146.
  • 27
    Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008; 152: 817-822.
  • 28
    Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008; 21: 339-348.
  • 29
    Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-187.
  • 30
    Giugliano D, De Rosa N, Di Maro G et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387-1390.
  • 31
    Dorella M, Giusto M, Da Tos V et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81: 1568-1574.
  • 32
    Braun B, Eze P, Stephens BR et al. Impact of metformin on peak aerobic capacity. Appl Physiol Nutr Metab 2008; 33: 61-67.
  • 33
    Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
  • 34
    Lira VA, Brown DL, Lira AK et al. Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol (Lond) 2010; 588: 3551-3566.
  • 35
    Sharoff CG, Hagobian TA, Malin SK et al. Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals. Am J Physiol Endocrinol Metab 2010; 298: E815-E823.
  • 36
    Kraus WE, Slentz CA. Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect. Obesity (Silver Spring) 2009; 17 Suppl 3: S21-S26.
  • 37
    Smith AC, Mullen KL, Junkin KA et al. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Am J Physiol Endocrinol Metab 2007; 293: E172-E181.
  • 38
    Iozzo P, Hallsten K, Oikonen V et al. Effects ofmetformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 2003; 26: 2069-2074.
  • 39
    Koh HJ, Hirshman MF, He H et al. Adrenaline is a critical mediator of acute exercise-induced AMP-activated protein kinase activation in adipocytes. Biochem J 2007; 403: 473-481.
  • 40
    Slentz CA, Houmard JA, Johnson JL et al. Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol 2007; 103: 432-442.